Abstract
Before the global distribution of COVID-19 vaccines, we observed substantial concerns among non-immunocompromised people about the lack of long-term research or the occurrence of adverse events after vaccination, and concerns among patients with immune-mediated inflammatory rheumatic diseases about interactions with their underlying autoimmune disease or immunosuppressive treatment regimens.1 Our findings have since been replicated,2,3 but there is as yet no data on how patients' thoughts and behaviour have evolved as vaccines were distributed, or data that compare COVID-19 vaccine coverage between patients with rheumatic immune-mediated inflammatory diseases and healthy controls.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
